Peptides: what physicians need to know
The questions people ask most about peptides, GLP-1s and how they are regulated, with the evidence for and against: PubMed-verified studies, regulators' decisions, news and the arguments of peptide supporters. Every fact is linked.
Articles
Evidence
Rare GLP1R Variants Blunt Semaglutide, Not Tirzepatide: ASHG Data
A Helix pharmacogenomic talk at ASHG 2026 reports that carriers of rare damaging GLP1R variants lost far less weight on semaglutide but nearly normal weight on tirzepatide. The carrier groups had 17 and 19 people, and the data are not peer reviewed.
Read article →
Evidence
GLP-1 RA: What GLP-1 Receptor Agonists Are
GLP-1 RA stands for GLP-1 receptor agonist: peptides engineered to switch on the receptor of a gut hormone without being destroyed within minutes. This guide explains how they were built, how they are classified and what the large trials showed.
Read article →
Regulation
FDA Orders NAION Warning on All GLP-1 Drugs: What the Data Show
On November 9, 2026, the FDA required non-arteritic anterior ischemic optic neuropathy (NAION) to be added to the warnings of every GLP-1 receptor agonist. The numbers are small, mixed and do not prove causation. Here is what physicians need to know.
Read article →
Regulation
First Sale Under HHS Peptide Enforcement Discretion: What It Means
A Nasdaq-listed pharmacy says it has made its first commercial sale of a compounded peptide under HHS's enforcement-discretion policy, which is still a draft. What that does and does not mean, and what physicians should ask.
Read article →
Evidence
Survodutide: No CV Safety Signal, but 1 in 5 Stopped Treatment
Survodutide, a glucagon/GLP-1 dual agonist, met its noninferiority goal for major cardiovascular events in SYNCHRONIZE-CVOT. What the result proves, what it does not, and why GI tolerability is the other headline.
Read article →
Regulation
Hims & Hers Sells Zepbound and Foundayo, Moving Away From Compounded GLP-1s
On November 6, 2026, Lilly and Hims & Hers announced that Hims patients can buy Lilly's tirzepatide and orforglipron without leaving the platform. What it means for 503A compounding and the wider peptide policy debate.
Read article →
Evidence
GLP-1 medications compared: every approved drug
Which GLP-1 medications exist, how their structure and duration of action differ, and what the cardiovascular safety trials and head-to-head studies showed.
Read article →
Health
Acne and rosacea: treatment and what peptide research shows
What acne and rosacea are, how guidelines treat them today, and what has been observed with LL-37, antimicrobial peptides, topical peptides and GLP-1 drugs.
Read article →
Health
Anxiety: treatment and what peptide research shows
What anxiety is, how it is treated today, and what Selank and intranasal oxytocin have shown: small trials, mixed results and weak evidence.
Read article →
Health
Sleep apnea: what it is, treatment and tirzepatide
What obstructive sleep apnea is, how it is diagnosed and treated today, and what tirzepatide showed in the SURMOUNT-OSA trial.
Read article →
Health
Knee osteoarthritis: treatment, GLP-1s and BPC-157
What knee osteoarthritis is, how it is diagnosed and treated today, and what semaglutide, retatrutide and BPC-157 have shown.
Read article →
Health
Advanced Prostate Cancer: Treatment and GnRH Evidence
What advanced prostate cancer is, how it is diagnosed, what guidelines recommend, and what peptide GnRH analogs (leuprolide, goserelin, degarelix) have shown compared with oral relugolix.
Read article →
Health
Cancer cachexia: treatment and what anamorelin evidence shows
What cancer cachexia is, how it is diagnosed, what guidelines recommend and what anamorelin, an oral ghrelin-receptor agonist approved only in Japan, has shown.
Read article →
Health
Depression: treatment and what peptide research shows
What depression is, how it is treated today and what has been observed with oxytocin, GLP-1s and Semax/Selank. None is approved for depression.
Read article →
Health
Erectile dysfunction: treatment and peptide evidence
What erectile dysfunction is, how it is diagnosed, standard PDE5 inhibitor treatment and what trials of PT-141 and kisspeptin have shown.
Read article →
Health
Chronic hepatitis B: treatment and what thymosin alpha-1 shows
What chronic hepatitis B is, how it is diagnosed, what guidelines recommend, and what trials of thymosin alpha-1 and the peptide bulevirtide in hepatitis D have shown.
Read article →
Health
Pulmonary arterial hypertension: treatment and sotatercept
What pulmonary arterial hypertension is, how it is treated today, and what endothelin antagonists, sotatercept and the VIP peptide have shown.
Read article →
Health
Male hypogonadism: treatment and what hCG and kisspeptin show
What male hypogonadism is, how it is diagnosed, what guidelines recommend, and what hCG, GnRH (gonadorelin) and kisspeptin have shown in men.
Read article →
Health
Infertility: treatment and what GnRH peptide research shows
What infertility is, how it is diagnosed, what guidelines recommend, and what GnRH antagonists (cetrorelix, ganirelix) and kisspeptin have shown in ovarian stimulation.
Read article →
Health
HFpEF: what the GLP-1 trials show (semaglutide, tirzepatide)
What heart failure with preserved ejection fraction is, how it is treated today, and what the semaglutide and tirzepatide trials show.
Read article →
Health
Migraine: treatment and what CGRP blockers show
What migraine is, how it is diagnosed and treated today, and what blockers of the peptide CGRP (antibodies and gepants) have shown.
Read article →
Health
Narcolepsy: treatment and what orexin research shows
What narcolepsy is, how it is diagnosed and treated today, and what orexin (hypocretin) and orexin receptor agonists have shown.
Read article →
Health
Osteoporosis: treatment and teriparatide evidence
What osteoporosis is, how it is diagnosed, what guidelines recommend, and what teriparatide, abaloparatide and calcitonin have shown against fractures.
Read article →
Health
Oxytocin in labor and postpartum: uses, risks, evidence
What postpartum hemorrhage and labor induction are, what guidelines recommend, and what oxytocin and carbetocin, two peptides with obstetric indications, have shown.
Read article →
Health
Parkinson's disease: treatment and what GLP-1 trials show
Parkinson's disease: symptoms, diagnosis, current treatment and what exenatide, lixisenatide and NLY01 showed in randomized trials.
Read article →
Health
Psoriasis: treatment and what icotrokinra shows
What psoriasis is, how guidelines treat it today and what has been observed with icotrokinra, the first oral peptide approved for psoriasis, and with LL-37.
Read article →
Health
Sarcopenia: what it is, treatment and what peptides show
What sarcopenia is, how it is diagnosed, what guidelines recommend and what GH secretagogues, anamorelin and GLP-1 drugs have shown about muscle.
Read article →
Health
Polycystic ovary syndrome: treatment and what GLP-1s show
What polycystic ovary syndrome (now PMOS) is, how it is diagnosed, what guidelines advise and what liraglutide, semaglutide and kisspeptin research has shown.
Read article →
Health
HIV: treatment and what peptide research has shown
What HIV is, how it is diagnosed, what guidelines recommend, and what trials of enfuvirtide, tesamorelin and thymosin alpha-1 have shown.
Read article →
Evidence
Mounjaro (tirzepatide): what it is, how it works, the evidence
Mounjaro (tirzepatide) is the first approved drug that activates both the GIP and GLP-1 receptors. What it is, how it differs from Ozempic and what the trials showed.
Read article →
Evidence
Peptides in cosmetics: types, mechanisms and real evidence
What cosmetic peptides in creams are, how they are classified (signal, neurotransmitter-inhibiting, enzyme-inhibiting and carrier), what Matrixyl, argireline and copper GHK-Cu do in skin, and what the trials actually show.
Read article →
Evidence
Peptides for weight loss: which ones have real evidence
A hugely searched question with a short answer: the peptides with phase 3 obesity trials are GLP-1 agonists and their combinations. Here is what they show, what sits behind the rest, and where the limits are.
Read article →
Evidence
Oral semaglutide pills: trials, evidence and safety
Semaglutide in pill (tablet) form: what Rybelsus and the Wegovy pill are, how a peptide is absorbed by mouth, and what the trials show against injectable semaglutide.
Read article →
Evidence
Tirzepatide side effects: what the trials show
Tirzepatide side effects and adverse events: how common nausea, diarrhea and vomiting are, what the data say on pancreatitis and gallbladder disease, and what the FDA label warns.
Read article →
Evidence
What Is Wegovy Used For? Semaglutide 2.4 mg Explained
What Wegovy is used for, which conditions its label covers, how it differs from Ozempic, and the trials behind each use of injectable semaglutide.
Read article →
Health
Endometriosis: what it is, treatment and the GnRH evidence
What endometriosis is, how it is diagnosed, what guidelines recommend, and what the peptide GnRH analogues (leuprolide, goserelin) have shown compared with oral antagonists.
Read article →
Regulation
Health Canada Seizes 11,400 Peptide Vials After Bacteria Found
Health Canada found three bacteria in unauthorized injectable peptides sold online and seized more than 11,400 vials. For US physicians, the lesson is that sterility and purity are separate tests.
Read article →
Regulation
NAD to Lilly's Rival: 'Personalized' Isn't Made-to-Order
The National Advertising Division recommended that Good Life Meds drop health-benefit and 'personalized' claims for its compounded 'Tirzepatide+'. What it means for clinicians who prescribe or refer.
Read article →
Evidence
BPC-157 and TB-500: a complete guide to evidence and safety
What BPC-157 and TB-500 are, how they work, what the human studies showed, what is known about their safety and quality, and what is still unproven.
Read article →
Evidence
Peptide quality: a complete guide to COA, HPLC and purity
What a COA measures, what HPLC purity means, how peptides degrade and what labs found in falsified products, in one evidence-based guide.
Read article →
Evidence
GHK-Cu: a complete guide to the copper peptide
What GHK-Cu is, how it works, what human trials show, its safety, its stability and what is still unknown, all on one page.
Read article →
Evidence
GLP-1 drugs: a complete guide to semaglutide and beyond
What GLP-1 is, how semaglutide, tirzepatide and retatrutide work, what the human trials show, the documented risks and what is still unknown.
Read article →
Evidence
Mitochondrial peptides: a complete guide to MOTS-c & SS-31
What MOTS-c, SS-31, NAD+ and epitalon are, how they act on mitochondria, what human trials showed and where the evidence ends.
Read article →
Evidence
Sleep and cognition peptides: a complete guide
DSIP, Semax, Selank and Pinealon: where they come from, the mechanisms claimed for them, what each human study showed, and where the evidence ends.
Read article →
Evidence
Sexual health peptides: a complete guide to PT-141
PT-141, melanotan, kisspeptin and oxytocin: how they act in the brain, what human trials showed, their risks and what is still unknown.
Read article →
Evidence
GH secretagogues: a complete guide to evidence and safety
Sermorelin, tesamorelin, CJC-1295 and ipamorelin: how they work, what human trials showed, what the risks are and what remains unproven.
Read article →
Regulation
FDA Warning Letter to Empower: Are Add-In GLP-1s Just Copies?
The FDA treated Empower Pharmacy's tirzepatide/niacinamide and semaglutide/cyanocobalamin as "essentially copies" of approved drugs and called the claimed differences "pretextual." What warning letter 738238 says, what it asks of prescribers, and what the other side argues.
Read article →
Regulation
FDA rejects 'research use only' labels: warning letters to five peptide sellers
On August 24, 2026, FDA sent warning letters to five online peptide vendors naming semaglutide, tirzepatide, retatrutide, tesamorelin, SS-31 and PT-141. Its argument: a 'research use only' label does not change what the website says.
Read article →
Regulation
LegitScript Opens Certification to BPC-157 and 5 Other Peptides
Since November 2, 2026, LegitScript, the certifier Google, Meta, Visa and Mastercard rely on, no longer treats offering BPC-157, TB-500, epitalon, semax, KPV or MOTS-c in the United States as an automatic barrier, as long as the HHS policy's conditions are met.
Read article →
Regulation
HHS Lets Pharmacies Compound 6 Peptides: What It Says
HHS issued an enforcement-discretion policy so pharmacies and physicians can compound BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 in the United States. What it covers, the conditions, what it is not, and why FDA scientists opposed it.
Read article →
Regulation
Coroner Links CJC-1295 and Ipamorelin to Actor's Death
A Victorian coroner found that a cardiac arrest followed injections of CJC-1295 and ipamorelin prescribed to Richard Norton, 75, and asked regulators to review whether they should be prescribable. What he said, what he did not, and why it matters in the United States.
Read article →
Regulation
Counterfeit Ozempic, compounded tirzepatide: indictment and recall
In September 2026 the U.S. Department of Justice charged two Indian nationals with smuggling counterfeit Ozempic from China, and FDA classified a North Carolina 503B outsourcing facility's recall of compounded tirzepatide vials for lack of sterility assurance. Two fronts in the same GLP-1 supply chain.
Read article →
Regulation
Peptide compounding policy: who is lobbying the White House
FDA's interim access policy for compounded peptides is under White House review, and six outside parties asked to be heard before it comes out. Who they are, what the document can and cannot do, and how thin the human evidence behind it still is.
Read article →
Clinical practice
What is a peptide? Explained in five minutes
If amino acids are letters, peptides are short words and proteins are books. This first step explains the basic idea, with insulin as the example.
Read article →
Regulation
Exosomes that aren't exosomes: what FDA found in 2025–2026
An August 2026 warning letter says a manufacturer's "exosome" process for hair, facial and sexual rejuvenation does not appear to isolate exosomes, and that its sterility tests were run on frozen samples. So what is in the vial going onto microneedled skin?
Read article →
Market
Retatrutide: Lilly takes an aesthetic clinic to court
In August 2026, Eli Lilly sued a California med spa, a compounding pharmacy and four sellers that label their products as laboratory reagents over a drug that is still in Phase 3. It says it has reported more than 200 individuals and entities to the FDA, the Justice Department and licensing boards. What changed for clinics that administer it.
Read article →
Evidence
GHK-Cu (copper peptide): the mechanism of action, step by step
From copper to matrix, from matrix to cell and from cell to gene: what has actually been measured about how GHK-Cu works in skin, with every human study we could verify.
Read article →
Clinical practice
Ozempic face and GLP-1 facial volume loss: the evidence
Ozempic face explained: the midface loses about 7% of its volume per 10 kg lost. Causes, hair loss and the evidence behind each treatment.
Read article →
Evidence
Peptides and skin healing: what the studies show for laser, microneedling and surgery
Thymosin β4, BPC-157 and GHK-Cu have decades of data in wounds, burns and scars, nearly all of it in animals. What the studies say, which molecule each one used, and what happened when thymosin β4 reached human trials.
Read article →
Trends
Exosomes versus peptides: what is actually being applied to the skin
Exosomes are the most visible trend in regenerative aesthetics. We explain what they are, why it is so hard to know what a vial contains and what the trials show, and we compare them with a drug class defined by its sequence.
Read article →
Evidence
Peptides and hair loss: copper, thymosin β4 and biomimetics against the evidence
The hair clinic now sees copper peptides, biomimetic lotions and patients shedding hair on GLP-1 drugs. Which molecule was studied, in what model and with what result, next to minoxidil and finasteride.
Read article →
Evidence
Matrixyl and signal peptides: what the skin trials show
A five-amino-acid fragment of type I procollagen became the most studied cosmetic peptide. Origin, mechanism, every vehicle-controlled trial that can be verified in PubMed, the comparison with tretinoin and how the penetration problem is being solved.
Read article →
Evidence
PRP in aesthetics: the biologic nobody questions
A peptide is asked for its sequence, its purity and a certificate of analysis. Platelet-rich plasma, which has none of the three, is asked for a centrifuge. What the evidence for PRP shows in hair, face, scars and melasma, and why aesthetic practice measures it with a different yardstick.
Read article →
Evidence
DSIP: what it is, sleep evidence and safety
What DSIP (delta sleep-inducing peptide) is, what human studies showed on sleep and withdrawal, what the FDA found on its safety, and what changed in 2026.
Read article →
Market
How a peptide is made: solid-phase synthesis explained for physicians
Behind every vial is more than sixty years of chemistry, honored with a Nobel Prize and now run at the scale of tons. Knowing how a peptide is built, what impurities it can carry and how it is controlled makes any analysis easier to read.
Read article →
Evidence
Peptides in oncology: the approved drugs already treating cancer
Long before semaglutide, peptides had earned a place in prostate cancer, neuroendocrine tumors and myeloma, with phase 3 trials published in the leading journals. This is a drug-by-drug review of that evidence.
Read article →
Market
Non-peptide oral GLP-1: orforglipron trials and approval
Orforglipron, the non-peptide oral GLP-1: phase 3 results, approval status (FDA, EMA) and how it differs from oral semaglutide.
Read article →
Trends
The other side: why doctors and patients defend peptides
The regulators' criticisms are real. So is the fact that more than 80 peptide drugs help millions of people today, that demand keeps growing and that many doctors see results in their practice. These are the arguments of peptide supporters, in their own words.
Read article →
Trends
A century of peptide therapeutics: from insulin to semaglutide
The first insulin injection was given in January 1922. A century later, more than 80 peptide drugs are on the market and GLP-1 analogues rank among the best-selling medicines in the world. This is the story of a mature drug class, and of how chemistry solved its limitations.
Read article →
Evidence
GLP-1s beyond weight: the hard-outcome trials
Heart attack, kidney, sleep apnea, fatty liver, heart failure and the knee: six areas where semaglutide or tirzepatide already has randomized phase 3 trials. This is the evidence that makes the class more than a weight-loss treatment.
Read article →
Evidence
Tirzepatide mechanism of action: GIP, GLP-1, the paradox
Tirzepatide mechanism of action: how it activates GIP and GLP-1 receptors, what each trial measured, and why the "obesogenic" GIP worked.
Read article →
Evidence
After semaglutide: CagriSema, orforglipron, MariTide and the estimand trap
The next generation of obesity drugs arrives with double-digit numbers. But the same molecule can "lose" 20.4% or 22.7% depending on the estimand. How to read the results before they reach the clinic.
Read article →
Evidence
Cagrilintide: what it does and how amylin works
What cagrilintide does: a weekly amylin analog that curbs appetite. What trials show, CagriSema's FDA filing, and where the evidence ends.
Read article →
Evidence
GLP-1s: muscle, rebound, eyes and pancreas. What the data say
Four questions dominate conversations about semaglutide and tirzepatide: do you lose muscle? does the weight come back when you stop? do they harm vision? and the pancreas? Answers from trials and regulators.
Read article →
Evidence
BPC-157 in the laboratory: tendon, gut and blood vessels
Three decades of animal models describe BPC-157 as a repair peptide with an unusual pattern: the same effect in tendon, gut mucosa and endothelium. What those studies show, tissue by tissue, which mechanisms independent laboratories confirmed, and where the evidence ends.
Read article →
Clinical practice
Semaglutide and alcohol: three trials and a warning removed
Patients reported it in the clinic: on GLP-1s they drank less. Between 2025 and 2026 three randomized trials arrived, one in The Lancet. And in January 2026 the FDA asked for the suicidal-ideation warning to be removed.
Read article →
Evidence
SS-31 (elamipretide): the mitochondrial peptide that reached the FDA
A tetrapeptide that binds cardiolipin in the inner mitochondrial membrane won FDA accelerated approval for Barth syndrome in 2025. What its trials showed, where they failed and what still needs confirming.
Read article →
Evidence
NAD+ in humans: precursors, infusions and what the trials measure
NAD+ declines with age in human tissues and its oral precursors raise it consistently. The clinical question is a different one: what changes in study subjects' outcomes, and what is known about NAD+ given directly by intravenous infusion.
Read article →
Evidence
BPC-157: from Rogan's podcast to an FDA vote
Robert F. Kennedy Jr. said he used it. An FDA committee voted 8 to 6 in its favor. And PubMed still has not one controlled trial in humans. What changed in 2026 and what did not.
Read article →
Trends
GLOW, KLOW and Wolverine: the logic of regenerative blends
Blends of BPC-157, TB-500, GHK-Cu and KPV bring four tissue-repair mechanisms into a single vial. The synergy hypothesis is appealing; the data that test it are only beginning.
Read article →
Evidence
Kisspeptin: real science, wrong molecule?
Human kisspeptin studies are among the best in this field: IVF, sexual desire, functional MRI. But almost all use single doses of kisspeptin-54 (subcutaneous injection or intravenous infusion) in a clinical or research setting. What circulates on the market is something else.
Read article →
Evidence
GLP-1s, dementia and Alzheimer's: what EVOKE showed
Do GLP-1 drugs prevent dementia? In type 2 diabetes they track with fewer cases, but in EVOKE semaglutide did not slow Alzheimer's. The full evidence.
Read article →
Trends
GHRP-6, GHRP-2 and ghrelin: when pharmacology discovered a hormone
In 1984 a synthetic hexapeptide released growth hormone while no one knew which receptor it acted on. Fifteen years later that question led to ghrelin and, later still, to drugs approved in Japan and the United States.
Read article →
Evidence
CJC-1295, ipamorelin and MK-677: the GH and IGF-1 debate
Raising growth hormone sounds like youth. Human studies show these compounds do raise it, and also what it costs and what is still unknown.
Read article →
Evidence
Tesamorelin: the GHRH analog that did clear the FDA
Among the peptides that stimulate growth hormone, tesamorelin is the one with phase 3 trials and FDA approval since 2010. Its data show what this mechanism achieves in humans and what it requires monitoring for.
Read article →
Evidence
MOTS-c: what it is, mechanism and human evidence
MOTS-c is a 16-amino-acid mitochondrial peptide that activates AMPK. Its mechanism, the human data (no native-peptide trials) and what changed in 2026.
Read article →
Trends
Epitalon, MOTS-c, NAD+ and SS-31: longevity between promise and proof
"Anti-aging" peptides are the fastest-growing part of the conversation. What do they have in common? A lot of interesting biology and no human evidence that they slow aging.
Read article →
Evidence
AOD-9604: the GH fragment meant to burn fat without touching glucose
A 16-amino-acid peptide derived from the C-terminus of growth hormone, with solid laboratory data, six human safety trials and a phase 2b trial that did not confirm weight loss.
Read article →
Evidence
TB-500 is not thymosin beta-4: fragment vs protein
Almost everything said about TB-500 comes from studies of full-length thymosin beta-4, a 43-amino-acid protein. TB-500 is a 7-amino-acid fragment. The FDA found no case in the medical literature of it being given to patients.
Read article →
Evidence
Oral collagen: the peptide your patients already take
Hydrolyzed collagen is probably the most widely consumed "peptide". Meta-analyses show benefits for skin and joints, but the skin effect fades when only independent or high-quality trials are analyzed.
Read article →
Evidence
Ipamorelin: the "selective" GH secretagogue, from Novo Nordisk's lab to postoperative ileus
Ipamorelin was the first secretagogue to release GH in animals without raising ACTH or cortisol. Its clinical program bet on postoperative ileus, not aging, and fell short there.
Read article →
Evidence
GHK-Cu: four decades of papers, few trials
The copper peptide is a cosmetics star and now a syringe star too. Topical trials give mixed results, the injectable route has no human trials, and about a third of the literature carries the same group's byline.
Read article →
Evidence
Sermorelin: what it is, evidence and regulatory status
What sermorelin is, how it acts on the GH axis, what its trials in children and adults showed, why it left the U.S. market, and where it stands in 2026.
Read article →
Evidence
PT-141 in men: a central, not vascular, mechanism
Before it was approved for women, bremelanotide was studied in men with erectile dysfunction, including men who did not respond to sildenafil. What those trials showed, how it acts on the MC4R receptor and where the evidence ends.
Read article →
Evidence
Semax, Selank and DSIP: what is behind the nootropic peptides
Semax is registered in Russia as nasal drops and promoted worldwide as a cognitive enhancer. Selank as an anxiolytic. DSIP for sleep. We review the trials and what the FDA found in 2026.
Read article →
Evidence
LL-37 and antimicrobial peptides: the body's answer to resistance
Humans make a single peptide of the cathelicidin family, LL-37, and its synthesis depends in part on vitamin D. Antimicrobial peptides are already in the pharmacy, but several new candidates have fallen by the wayside.
Read article →
Evidence
CJC-1295 and DAC: the GHRH analog that anchors to albumin
A GHRH fragment acts for minutes. By binding it covalently to albumin, CJC-1295 stretched its effect to days in healthy adults without erasing the natural GH pulse. What the studies showed, how it differs from the "no-DAC" version, and why its development stopped.
Read article →
Evidence
Melanotan II and PT-141: chemical cousins, opposite stories
Both act on melanocortin receptors. One went through phase 3 trials and is approved. The other is sold for tanning and has a growing list of reports of new moles and melanomas. Why the difference.
Read article →
Evidence
IGF-1 LR3 and mecasermin: the lab analog and the approved drug
IGF-1 has had an approved drug since 2005, mecasermin, with a narrow pediatric indication and a demanding label. IGF-1 LR3 is a different molecule: an analog engineered to escape the binding proteins, highly potent in the lab and with animal data only.
Read article →
Clinical practice
Peptide Certificate of Analysis: How to Read One
What a peptide certificate of analysis should show: HPLC, mass spectrometry, net content, water and endotoxins, and how a peptide or blend is identified.
Read article →
Evidence
Thymosin alpha-1 after TESTS: two large negative trials
It is sold as an "immune optimizer". It is approved in more than 35 countries for hepatitis B and C. But two large double-blind trials, in sepsis and in pancreatitis, showed no benefit. And in patients under 60 a signal pointed the other way.
Read article →
Evidence
5-amino-1MQ: what the NNMT inhibitor does and where the evidence ends
5-amino-1MQ sits in peptide catalogs, but it is a small molecule that blocks the enzyme NNMT. In mice it was associated with less fat, better metabolism and stronger aged muscle; in humans there are still no published trials.
Read article →
Evidence
SNAP-8 and argireline: "topical Botox" under the microscope
SNAP-8 and its predecessor, argireline, mimic a fragment of SNAP-25 to dampen the contraction behind expression lines. The mechanism is elegant and the human trials are positive, but small; the skin is the main barrier.
Read article →
Clinical practice
Peptide stability: from lyophilized powder to reconstituted vial
A well-kept peptide is a reliable data point. The chemistry of degradation is well understood: moisture, temperature, light, pH, surfaces and agitation. This is the protocol that follows from the literature and from the labels of approved peptides.
Read article →
Clinical practice
GLP-1s: interactions, bone, micronutrients and the "microdosing" fad
What gets missed in the clinic: hypoglycemia with sulfonylureas, rising levothyroxine, a shifting INR, falling vitamin D, bone density, and a trend with no trial behind it.
Read article →
Clinical practice
Full stomach despite fasting: GLP-1s, sedation and the 2024 reversal
In 2023 the ASA asked for weekly GLP-1s to be held for a week before surgery. In 2024 five societies said the opposite. Gastric ultrasound data from 2026 show why the debate is not over.
Read article →
Evidence
Epitalon: Khavinson's program, telomerase and what still needs replication
Epitalon (Ala-Glu-Asp-Gly) is the product of more than four decades of research by Vladimir Khavinson's group in St. Petersburg. Its hypothesis is coherent and its animal safety reports are favorable; what is missing is independent replication and controlled human trials.
Read article →
Clinical practice
GLP-1s and thyroid cancer: from rat C-cells to Nordic registries
The boxed warning is still on the label. A French study found a signal; the large registries that followed did not. What we know in 2026, and what still cannot be ruled out.
Read article →
Clinical practice
Compounded GLP-1s: salts, impurities and antibodies
990 adverse-event reports with compounded semaglutide and more than 730 with tirzepatide. A new impurity in B12 blends. And a little-known fact: even the branded product triggered antibodies in nearly two out of three patients in its trials.
Read article →
Market
Glutathione skin lightening: evidence and IV safety
Does glutathione lighten skin? Oral and topical: a modest effect that fades. IV glutathione: one trial and 2026 FDA and CDC safety alerts.
Read article →
Market
What is really in the vial? What the labs found
Semaglutide at 7.7% purity. Arsenic and lead. Bacteria. Growth hormone with less than the label says. What studies found when they tested peptides bought outside the regulated supply chain.
Read article →
Evidence
Intranasal oxytocin: anatomy of a replication crisis
The "love hormone" promised to improve social behavior, autism and even obesity. When the large trials came, the main effects were not confirmed. A case study in how to read the evidence for a peptide.
Read article →
Trends
RAADfest: two women in critical care after peptide injections
At a longevity festival in Las Vegas, two attendees received peptide blends at a booth. One reached the hospital already intubated. Fines came seven months later, but the vials were never tested.
Read article →